Semaglutide More Than Doubled Likelihood of MASH Resolution

Semaglutide (Wegovy; Novo Nordisk) more than doubled the likelihood that patients with metabolic dysfunction–associated steatohepatitis (MASH) saw their liver disease resolve without their fibrosis worsening, according to a systematic review and meta-analysis recently published in Medicine.¹

Growing Burden of MASH Drives Search for New Therapies

Metabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease worldwide, affecting roughly one-quarter to one-third of adults, with rising prevalence driven by increasing rates of obesity and type 2 diabetes. Its more severe form, MASH, can progress from liver inflammation and fibrosis to cirrhosis and hepatocellular carcinoma. Despite its growing burden, effective, approved pharmacologic treatments for MASH remain limited, highlighting the need for new therapeutic options, particularly ones that can more reliably reverse fibrosis, which current MASH therapies have struggled to do.

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist approved for diabetes and obesity,^2,3 has shown potential benefits in MASLD and MASH through its effects on glucose control, weight loss, and metabolic health. Previous studies have evaluated its impact on liver outcomes, but limitations in trial designs and patient populations have made it difficult to determine its independent efficacy.

Because of these limitations, the current study pooled results from 4 randomized controlled trials to provide an updated assessment of semaglutide’s effectiveness and safety for improving key MASLD and MASH outcomes. Encompassing nearly 1500 participants with MASLD or MASH, the study durations ranged from 48 to 72 weeks, and semaglutide doses ranged from 0.1 mg daily to the 2.4 mg weekly dose used in obesity and, more recently, liver disease treatment.

Semaglutide Improved MASH Resolution but Not Fibrosis

The analysis showed that semaglutide significantly increased the likelihood of resolving steatohepatitis without worsening fibrosis compared with placebo (risk ratio [RR], 2.14; 95% CI, 1.44-3.17; P = .0002). The drug also produced a significant reduction in aspartate aminotransferase (AST), a liver enzyme marker of active inflammation (mean difference [MD], −6.72 U/L; 95% CI, −11.79 to −1.64; P = .009), and a numerically larger, though not statistically significant, drop in alanine aminotransferase.

By contrast, semaglutide did not show a statistically significant benefit for reducing fibrosis without worsening steatohepatitis (RR, 1.14; 95% CI, 0.63-2.05; P = .67). Similarly, the drug showed no significant improvement in liver stiffness measurements. The authors noted this distinction is clinically important, since fibrosis stage, more than steatohepatitis activity alone, is considered the strongest predictor of liver-related mortality in MASLD or MASH.

Semaglutide's metabolic effects were more consistent. The pooled analysis found a substantial reduction in hemoglobin A_1c (MD, −1.29%; 95% CI, −1.46 to −1.13; P < .00001) compared with placebo, with low heterogeneity across trials, indicating a consistent effect. Semaglutide also produced significantly greater weight loss (MD, −6.99%; 95% CI, −13.92 to −0.06; P = .05), though the heterogeneity was high, indicating wide variation in results across the individual trials.

Regarding safety, semaglutide carried a modestly higher overall risk of treatment-emergent adverse events (RR, 1.09; 95% CI, 1.04-1.14; P = .0004), driven primarily by gastrointestinal symptoms; diarrhea (RR, 1.98; 95% CI, 1.54-2.54; P < .00001), nausea (RR, 2.88; 95% CI, 2.27-3.65; P < .00001), and vomiting (RR, 3.70; 95% CI, 2.47-5.54; P < .00001) were all significantly more common with semaglutide. Serious adverse events and treatment discontinuation rates did not differ significantly from placebo, which the researchers suggested was generally manageable rather than treatment-limiting.

The meta-analysis comes approximately a year after the FDA granted accelerated approval to semaglutide for MASH with liver fibrosis,⁴ based on part 1 of the phase 3 ESSENCE trial (NCT04822181), which was 1 of the 4 studies included in this pooled analysis. The approval made semaglutide the second systemic therapy for MASH, following resmetirom (Rezdiffra; Madrigal Pharmaceuticals) in 2024,⁵ and the first GLP-1 receptor agonist to reach the liver disease market.

Future Research Needed to Optimize Treatment Strategies

The authors acknowledged several limitations of their study, including that trial durations of 48 to 72 weeks are too short to assess whether histologic gains translate into reduced rates of cirrhosis or mortality over the long term.¹ They also cautioned that the included trials used strict eligibility criteria that may not reflect the broader, more heterogeneous population of patients seen in everyday practice. Based on these limitations, the researchers suggested areas for further research.

"Future studies should prioritize longer follow-up periods, optimization of dosing strategies, and exploration of combination therapies with antifibrotic agents to address the ongoing unmet need for effective fibrosis reversal in advanced [MASH]," they concluded.

References

1. Khan S, Jamal A, Qadri M, et al. Therapeutic role of semaglutide in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of placebo-controlled trials with GRADE evidence assessment. Medicine. 2026;105(30):e49916. doi:10.1097/MD.0000000000049916
2. Caffrey M. FDA approves semaglutide, Novo Nordisk’s, once-weekly GLP-1 for type 2 diabetes. AJMC^®. December 5, 2017. Accessed July 28, 2026. https://www.ajmc.com/view/fda-approves-semaglutide-novo-nordisks-onceweekly-glp1-for-type-2-diabetes
3. Inserro A. FDA clears semaglutide for weight loss when used with diet, exercise. AJMC. June 4, 2021. Accessed July 28, 2026. https://www.ajmc.com/view/fda-clears-semaglutide-for-weight-loss-when-used-with-diet-exercise
4. Klein H. FDA approves semaglutide for MASH with fibrosis. AJMC. August 18, 2025. Accessed July 28, 2026. https://www.ajmc.com/view/fda-approves-semaglutide-for-mash-with-fibrosis
5. Joszt L. FDA approves resmetirom, first treatment for NASH with liver fibrosis. AJMC. March 14, 2024. Accessed July 28, 2026. https://www.ajmc.com/view/fda-approves-resmetirom-first-treatment-for-nash-with-liver-fibrosis